Chemotherapeutic Candidate Inducing Immunological Death of Human Tumor Cell Lines
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-γ and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.
Abstract
The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-γ and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.
참고문헌 (9)
- 오수진, "Cellular Mechanism of Newly Synthesized Indoledione Derivative-induced Immunological Death of Tumor Cell", Immune Network, 11(6), pp.383~389 (2011), 대한면역학회
- Obeid M, "Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from silent to immunogenic", Cancer Res, 67, pp.7941~7944 (2007)
- Zitvogel L, "Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway", Clin Cancer Res, 16, pp.3100~3104 (2010)
- Panaretakis T, "Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death", EMBO J, 28, pp.578~590 (2009)
- Obeid M, "Calreticulin exposure dictates the immunogenicity of cancer cell death", Nat Med, 13, pp.54~61 (2007)
- Gardai SJ, "Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte", Cell, 123, pp.321~334 (2005)
- Lee H, "Modulation of IFN-gamma production by TNF-alpha in macrophages from the tumor environment: significance as an angiogenic switch", Int Immunopharmacol, 6, pp.71~78 (2006)
- Esumi N, "Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression", Cancer Res, 51, pp.1185~1189 (1991)
- Janelidze S, "Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas", J Immunother, 32, pp.593~601 (2009)